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Ab s t r a c t
Introduction: Barrett’s esophagus (BE) is a state in which the distal portion of esophageal mucosa becomes lined with
cylindrical epithelium as a result of adaptive remodeling. It is widely accepted that the metaplastic lesions result from
chronic irritation with gastric and/or duodenal contents in the course of reflux disease. For many years, research cen-
tered on the risk factors of BE and resulting adenocarcinoma. Anti-reflux operations are the only procedures which
offer the possibility of treating the cause by restoring the anatomic barrier responsible for guarding against irritating
effects of gastroduodenal content on the distal esophagus. Total (i.e. 360°) laparoscopic Nissen fundoplication (LNF)
is considered the most effective amongst these procedures. Still, controversies related to the indications for anti-reflux
surgery are frequently encountered.
Aim: Retrospective analysis of long-term treatment outcomes in patients with BE subjected to laparoscopic Nissen
fundoplication.
Material and methods: The group included 42 BE patients, amongst them 30 men and 12 women. Initially, all the
patients were treated conservatively for at least 1 year. The subgroup with dysplasia was subjected to preoperative
argon plasma coagulation (APC). From 1 year after surgery (laparoscopic Nissen fundoplication), control biopsy spec-
imens were obtained from the gastroesophageal junction of all the patients.
Results: None of the patients showed the development of esophageal adenocarcinoma during the follow-up period.
Furthermore, no cases of dysplasia progression or de novo development of dysplasia were observed in the analyzed
group. In the initial 12-24 months after surgery, complete regression of metaplasia was documented in 7 (31.8%)
patients from group A, and a reduction in the area of Barrett’s metaplasia was observed in another 7 patients (31.8%).
Throughout the period of this study, persistent planoepithelial re-epithelialization was observed in 14 (70%) group B
patients, i.e. in individuals with baseline dysplasia subjected to preoperative argon plasma ablation. In the remaining
patients of this group, the developed changes of BE character were less advanced than at baseline.
Conclusions: Our opinion is that laparoscopic Nissen fundoplication, as a result of high effectiveness, represents the
method of choice in the treatment of BE in the case of patients who were qualified for surgery.
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Introduction
Barrett’s esophagus (BE) is a state in which the dis-
tal portion of the esophageal mucosa becomes lined
with cylindrical epithelium as a result of adaptive 
re modeling. The replacement of normal squamous
epithelium with glandular epithelium can be observed
on microscopic examination (Photo 1). It is widely ac -
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cepted that the metaplastic lesions result from chron-
ic irritation with gastric and/or duodenal contents in
the course of reflux disease. Also, as a result of adap-
tive remodeling of the esophagus, the Z line does not
correspond to the upper threshold of gastric folds.
Many authors consider BE as the most advanced
stage of gastroesophageal reflux disease (GERD). Al -
though the hypothesis on the close association be -
tween glandular metaplasia of the gastroeso phageal
junction and the risk of esophageal adenocarcinoma is
widely accepted, the exact mechanisms behind this
relationship are not fully understood. In view of the 
discrepancies with regards to the possible clinical pic-
ture, frequent modifications of disease definition, and
poorly understood pathogenic mechanisms of BE,
a unified diagnostic and therapeutic algorithm has not
been developed thus far for this group of patients [1].
Control of duodenogastroesophageal reflux con-
stitutes the principal therapeutic objective in BE pa -
tients [2]. Anti-secretive pharmacotherapy, mostly
with proton pump inhibitors (PPIs), is of vital impor-
tance. However, according to numerous authorities,
commonly used PPIs only attenuate the symptoms of
reflux, but do not completely normalize pH of the dis-
tal esophagus [2]. Additionally, such negative conse-
quences of chronic PPI administration as hypergas-
trinemia, and disturbances of the bacterial gastric
microflora, potentially promoting the development of
some malignancies, should not be underestimated.
Even assuming that PPIs effectively reduce gastric
secretion of acids, decidedly, they do not play an
important role in the case of non-acidic reflux. More-
over, it should be emphasized that bile acid salts, 
the principal components of alkaline refluxate, play
a particularly important role in the promotion of
esophageal adenocarcinoma development [3-5].
For many years, research centered on the risk fac-
tors of BE and resulting adenocarcinoma. Although
the role of chronic irritation of the distal esophageal
mucosa with refluxate is unquestionable, still it re -
mains unexplained why some patients develop solely
mucosal inflammation, while Barrett’s metaplasia is
observed in others. According to the literature, the
risk factors of BE include duration of exposure and
the composition of the refluxate. Furthermore,
a number of authors point out that the effective sup-
pression of gastric secretion not only leads to pla-
noepithelial re-epithelialization, but is also reflected
by reduced expression of certain proliferation-specif-
ic biomarkers [6].
Anti-reflux operations are the only procedures
which offer the possibility of treating the cause by re -
storing the anatomic barrier responsible for guarding
against irritating effects of gastroduodenal content
on the distal esophagus [7]. Total (i.e. 360°) Nissen
fundoplication (NF) is considered the most effective
amongst these procedures [8]. According to many
authors, the laparoscopic version of this procedure
(LNF) represents a gold standard in patients qualified
for surgical treatment due to both uncomplicated
GERD and GERD associated with Barrett’s metaplasia
[9, 10].
Still, controversies related to the indications for
anti-reflux surgery are frequently encountered. Most
BE patients are qualified for LNF on the basis of the
same criteria as subjects with uncomplicated GERD.
These indications seem particularly justified in the
case of younger patients, potentially exposed to
a chronic injury of the esophageal mucosa. Perhaps
the fact that more than one-third of BE patients do
not experience reflux symptoms requiring chronic
pharmacotherapy makes them one of the groups
which can benefit from LNF. Due to the lack of phar-
macological agents efficient against this condition,
confirmed non-acidic reflux is deemed to constitute
another important indication for surgical treatment.
The techniques of endoscopic ablation are used as
an adjunct to surgical procedures in patients with dys-
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Photo 1. Barrett's metaplasia – the glandular
epithelium, intestinalisation without dysplasia.
Histochemical staining Alcian blue + PAS (pH
2.5) – acidic mucus tinged with blue, neutral red,
pink, 20× lens (courtesy of Dr. K. Urbańczyk –
Department of Pathology, Jagiellonian Universi-
ty Medical College)
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plasia of metaplastic epithelium. Such techniques,
including argon plasma ablation, enable the re-epithe-
lialization of the gastroesophageal junction [11].
Aim
The aim of this study was to perform a retrospec-
tive analysis of long-term treatment outcomes in pa -
tients with BE subjected to laparoscopic Nissen fun-
doplication.
Material and methods
A total of 168 laparoscopic Nissen fundoplications
were performed in reflux disease patients of the Sec-
ond Department of Surgery, Jagiellonian University Me -
dical College, between January 1st, 2001 and April 30th,
2012. This group included 42 BE patients, amongst
them 30 men and 12 women. Mean age of enrolled
patients was 49 years, and mean duration of follow-
up amounted to 62 months (range: 3-94 months).
Endoscopic examination of the upper gastroin-
testinal tract was conducted in all patients during the
preparatory period before surgery, and biopsy speci-
mens were obtained from four esophageal quadrants
to confirm the diagnosis. The biopsies were taken at
1 cm intervals at the level of the metaplastic seg-
ment, in accordance with the recommendations of
the Montreal consensus (2006). Control endoscopy
was performed 12 months after surgery. If persistent
metaplastic lesions were observed, further control
endoscopies were performed on an annual basis.
Initially, all the patients were treated conserva-
tively (life style modification, dietary changes, PPIs)
for at least one year. Mean duration of therapy was
2.5 years (range: 1-4 years).
Signs of dysplasia in the baseline specimens of
gastroesophageal junction mucosa were observed in
20 (47.6%) of the patients. This subgroup was sub-
jected to preoperative argon plasma coagulation
(APC) in order to eliminate dysplasia, since the lack of
the latter was required to perform LNF. Endoscopic
ablation was not performed in the remaining 
22 (52.4%) patients with no signs of dysplasia within
the metaplastic epithelium.
During the surgery, diaphragmatic crura were
sewn together in all the patients irrespective of the
size of the hiatal hernia. The thoracic esophagus was
mobilized up to 7 cm above the hiatal line. Both the
diaphragmatic crura and the fundoplication wrap
were sutured using non-absorbable stitches.
A complete circular metaplastic segment was
revealed in 27 (64.3%) patients, while 15 (35.7%) pa -
tients presented with incomplete circular metaplasia.
The classic (> 3 cm) BE was observed in 25 (59.5%)
patients. Maximal extent of metaplasia in this group
of patients was 5 cm. The “short segment” type of BE
was documented in 17 (40.5%) individuals. On preop-
erative endoscopy, 38 (90.5%) patients showed slid-
ing hiatal hernia; 4 subjects (9.5%) had mixed type of
hiatal hernia.
One year after surgery, control biopsy specimens
were obtained from the gastroesophageal junction of
all the patients.
For the purpose of further analysis, the patients
were divided into two groups based on the lack
(group A) or presence of dysplasia (group B).
Results
None of the patients showed the development of
esophageal adenocarcinoma during the follow-up pe -
riod. Furthermore, no cases of dysplasia progression
or de novo development of dysplasia were ob served
in the analyzed group. In 36 (85.7%) subjects, laparo-
scopic Nissen fundoplication was reflected by the
attenuation of reflux disease symptoms during the
observation period. Thirty-three (78.6%) patients
reported transient swallowing disorders during the
first 2 months after surgery. These complaints did not
require hospitalization and resolved spontaneously in
most cases. Nine (21.4%) patients were treated suc-
cessfully with oral hydroxyzine (2 × 25 mg).
In the first 12-24 months after surgery, complete
regression of metaplasia was documented in 7 (31.8%)
patients from group A, and a reduction in the area of
Barrett’s metaplasia was observed in another 7 pa -
tients (31.8%). The remaining 8 (36.4%) patients did
not show any endoscopically or histopathologically
evident changes. The effects of anti-reflux therapy
were observed in patients with no baseline signs of
dysplasia, with gastric metaplasia (n = 3), and with
complete intestinal metaplasia (n = 4); the so-called
“short segment” type lesions were observed in all
these patients. Throughout the period of this study,
persistent planoepithelial re-epithelialization was
observed in 14 (70%) group B patients, i.e. in individ-
uals with baseline dysplasia subjected to preopera-
tive argon plasma ablation. In the remaining patients
of this group, the developed changes of BE character
were less advanced than at baseline.
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Discussion
Barrett’s esophagus represents the most seri-
ous complication of gastroesophageal reflux disease,
being an established precancerous lesion. While
one can easily find the therapeutic recommenda-
tions regarding uncomplicated GERD in the avail-
able literature, the management of patients with
glandular esophageal metaplasia still raises many
questions.
Progression of Barrett’s metaplasia towards eso -
phageal adenocarcinoma results from chronic reflux-
ate-induced injury of the esophageal mucosa. While
BE is a reversible state, persistent chronic inflamma-
tion promotes carcinogenesis [12]. Chemical compo-
sition of the refluxate seems to play an exceptionally
important role in BE pathogenesis; specifically, the
concentration of bile acids in reflux content is partic-
ularly correlated with the degree of esophageal mu -
cosal injury [13].
It is widely accepted that controlling the signs 
of gastroesophageal reflux disease constitutes the
principal therapeutic objective [2]. Achieving this
therapeutic effect requires normalization of pH at 
the esophageal-gastric junction; this goal is mostly
achieved with proton pump inhibitors (PPI). This ap -
proach attenuates the signs of reflux disease by
reducing the intensity of inflammatory lesions in the
distal esophagus. However, a number of authors
point to the limited value of such an approach in
some patients. Mikes and Gerson observed persist-
ent acidic reflux on pH-metric examination in 50% of
asymptomatic patients treated with PPIs [14]. Also,
the evidence of negative consequences associated
with persistent hypergastrinemia should not be under-
estimated.
Anti-reflux surgery, optimally performed laparo-
scopically, remains an alternative therapeutic ap -
proach as the only modality of treating the cause in
patients with dysfunction of the lower esophageal
sphincter. Such treatment enables restoration of the
physiological barrier reducing exposure of the esoph-
agus to reflux content.
Reduction of the area of glandular metaplasia
constitutes the principal component of adjunctive
treatment in BE patients. Most commonly, ablation
techniques are recommended in patients with asso-
ciated dysplasia. The most popular methods include
photodynamic technique, ablation with radiofrequen-
cy waves, and argon plasma ablation.
All the above-mentioned facts unambiguously
substantiate administration of chronic anti-secretory
therapy in the majority of BE patients. Currently,
most authors recommend basing the therapy on
PPIs, although a unified therapeutic protocol has not
been developed thus far. The most frequently postu-
lated protocol is based on over-the-standard dosage
of PPIs; however, this approach is associated with
established, more severe, and prolonged course of
reflux disease in BE patients as compared to the
group with uncomplicated GERD. The available litera-
ture contains reports suggesting the possibility of
complete remission of glandular metaplasia in pa -
tients treated solely with PPIs; nevertheless, authors
assign varying significance to these findings. In
a double-blinded randomized study, Peters observed
a complete remission of Barrett’s metaplasia in 8% of
patients subjected to 24 months of continuous ther-
apy with 80 mg of omeprazole [15]. Simultaneously,
there were no cases of complete regression of meta-
plastic lesions documented in a ranitidine-treated
group. In the opinion of the majority of authors,
chronic administration of proton pump inhibitors can
lead only to reduction of the metaplastic area with
potential development of islets lined with normal
squamous epithelium [16, 17]. However, according to
some opinions, the residual foci of metaplastic epithe-
lium can be localized deeper than the newly formed
islets, raising the question about the effectiveness of
the aforementioned therapeutic approach.
The above-mentioned data suggest that pharma-
cotherapy alone is not reflected by regression of glan-
dular metaplasia in the majority of BE patients and
does not enable planoepithelial re-epithelialization.
There is increasing evidence of the necessity of
implementing one of the ablation techniques at the
early stage of treatment in order to remove the meta-
plastic foci frequently associated with dysplasia.
Combining endoscopic techniques with anti-secreto-
ry therapy is also reflected by persistent planoepithe-
lial re-epithelialization [18]. In our study, the combi-
nation of argon plasma ablation with laparoscopic
Nissen fundoplication enabled persistent elimination
of Barrett’s metaplasia in approximately 70% of the
patients. However, the available literature lacks un -
ambiguous confirmation of the protective effect of
such an approach with regards to the risk of eso -
phageal adenocarcinoma; this necessitates further
research on the problem in question [19, 20].
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Anti-reflux surgery has become a common com-
ponent of treatment, particularly due to the popular-
ization of the laparoscopic approach. Pharmacother-
apy enables a transient normalization of pH at the
esophageal-gastric junction, but does not modulate
the efficiency of the physiological anti-reflux barrier.
Patients subjected to argon plasma ablation of meta-
plastic mucosa require long-term elimination of the
harmful effect of stomach-regurgitated content in
order to establish the therapeutic outcome. Nissen
fundoplication is currently postulated as the most
efficient modality of reflux treatment. Many authors
consider the laparoscopic form of this procedure as
a gold standard of GERD therapy. Surgical treatment
seems particularly substantiated in BE patients, par-
ticularly in those lacking reflux symptoms. According
to Sharma, surgical treatment plays a vital role in the
management of BE patients, as well as in the preven-
tion of BE-induced esophageal adenocarcinoma [21].
The outcomes of laparoscopic anti-reflux surgery
proved excellent with regards to the attenuation of
reflux symptoms. In Parill’s study, the control of GERD
symptoms was achieved in 91% of operated patients
[22]. In Eubanks’ analysis, mean 43-month postsurgi-
cal follow-up revealed a 95% reduction of reflux dis-
orders [23]. In our study, the typical GERD-related
complaints resolved in 86% of patients analyzed dur-
ing the period of the experiment.
According to numerous authors, there is a pre-
dominance of alkaline component of the reflux in
patients with BE [24, 25]. The authors of previous re -
ports emphasize that the degree of esophageal
mucosal exposure to bile content in BE patients is
similar to that observed in individuals subjected to
partial gastric resection. These facts point to limited
effectiveness of pharmacotherapy in this group of
patients. Consequently, surgical restoration of the
anti-reflux barrier should be markedly more effective
in the normalization of this type of reflux. In Parilla’s
study, limited exposure to bile content was observed
in 92% of the patients subjected to the anti-reflux
procedure and in only 25% of individuals treated with
PPI [22]. Consequently, it could be expected that the
outcomes regarding reduction of the metaplastic
area and the prevention of dysplasia and develop-
ment of malignancy would be markedly better in sur-
gically treated patients than in those in whom abla-
tion techniques were combined with anti-secretory
pharmacotherapy.
Current research suggests the possibility of com-
plete regression of metaplasia after surgical correc-
tion of an inefficient anti-reflux barrier. This phenom-
enon was observed in 4 out of 10 surgically treated
patients included in Brand’s study, the findings of
which were published in 1980 [26]. In Oelschlager’s
report, during the mean 40-month follow-up period,
the complete remission of metaplasia was revealed
in 33% of 106 cases of laparoscopically operated
patients with short BE. The results of previous analy-
ses suggest that such an approach can be effective in
no more than 20% of patients with classic BE. Also,
reports suggesting the possibility of regression of BE-
related dysplasia can be found in the available litera-
ture [27-29]. The results of these studies suggest that
complete regression of mild dysplasia can be ob -
tained in even up to 70% of the patients. Complete
regression of glandular metaplasia was documented
in seven of the analyzed patients with short BE.
The prevailing opinion indicates that Nissen fun-
doplication, as a result of high effectiveness, repre-
sents the method of choice in the treatment of BE in
the case of patients who were qualified for surgery.
However, such a consistent attitude is lacking with
regards to the details of its modifications. Early expe-
riences with LNF were limited to mobilization of the
esophagus solely at the level of the esophageal hia-
tus. Currently, according to the recommendations of
acknowledged authorities, the threshold of mobiliza-
tion should be placed much higher (Photo 2). Howev-
er, there are some discrepancies with regards to the
level of esophageal mobilization in the mediastinum.
According to Dallemagne, the esophagus should be
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Photo 2. Laparoscopic Nissen fundoplication –
intraoperative view during preparation of the
esophagus within the mediastinum
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mobilized up to 5-7 cm above the esophageal hiatus
[30]. In contrast, Swanstrom defines this threshold 
at the level of inferior pulmonary veins [31]. Such
a maneuver enables the restoration of a sufficiently
long abdominal section of the esophagus, which
seems to be one of the most important components
of the anti-reflux barrier. Furthermore, high mobiliza-
tion of the esophagus along with tighter than previ-
ously postulated suturing of the diaphragmatic crura
prevents translocation of the fundoplication wrap
into the mediastinum. According to Hunter et al., this
complication represents the most frequently reported
reason for re-operation in this group of patients [32].
Many surgeons believe that the diaphragmatic
crura should be sutured together only in the case of
evident signs of hiatal hernia. However, according to
increasing evidence, the tight binding of the crura in
all patients subjected to fundoplication constitutes
one of the main determinants of a successful out-
come. According to recently published opinions, such
an approach does not increase the risk of dysphagia
symptoms. Transient problems with swallowing, which
were also observed in our patients, probably result
from transient swelling of the esophagus at the level
of the fundoplication wrap. Additionally, normal swal-
lowing can be impaired in some patients as a result of
stress, as confirmed by high effectiveness of sedative
agents. However, most of such complaints resolve
spontaneously; intervention is required rarely, and
most commonly is limited to endoscopic balloon
dilatation.
References
1. Caygill CP, Watson A, Reed PI, Hill MJ. UK National Barrett's
Oesophagus Registry (UKBOR) and the 27 Participating Centres.
Characteristics and regional variations of patients with Barrett's
oesophagus in the UK. Eur J Gastroenterol Hepatol 2003; 15:
1217-22.
2. Sampliner RE. Practice Parameters Committee of the American
College of Gastroenterology. Updated guidelines for the diagno-
sis, surveillance, and therapy of Barrett's esophagus. Am J Gas-
troenterol 2002; 97: 1888-95.
3. Gutschow CA, Schröder W, Hölscher AH. Barrett's esophagus:
what is the poison – alkaline, biliary or acidic reflux? Dis Esoph-
agus 2002; 15: 5-9.
4. Kauer WK, Stein HJ. Role of acid and bile in the genesis of Bar-
rett's esophagus. Chest Surg Clin N Am 2002; 12: 39-45.
5. Nason KS, Farrow DC, Haigh G, et al. Gastric fluid bile concentra-
tions and risk of Barrett's esophagus. Interact Cardiovasc Thorac
Surg 2007; 6: 304-7.
6. Hongo M. Barrett's oesophagus and carcinoma in Japan. Aliment
Pharmacol Ther 2004; 20 Suppl 8: 50-4.
7. Tarnowski W, Kiciak A, Borycka-Kiciak K, et al. Laparoscopic fun-
doplication improves oesophageal motility – a prospective study.
Videosurgery Miniinv 2011; 6: 73-83.
8. Szyca R, Leksowski K, Cornelia de Lange syndrome – character-
istics and laparoscopic treatment modalities of reflux based on
own material. Videosurgery Miniinv 2011; 6: 173-7.
9. Wróblewski T, Skalski M, Ziarkiewicz-Wróblewska B, et al. New
antireflux surgical technique in GERD treatment. Videosurgery
Miniinv 2007; 2: 139-44. 
10. Wróblewski T, Skalski M, Ziarkiewicz-Wróblewska B, et al.
Progress in surgical treatment of reflux disease. Videosurgery
Miniinv 2006; 1: 121-4.
11. Migaczewski M, Budzyński A, Rembiasz K. Argon plasma coagu-
lation (APC) for treatment of Barrett’s oesophagus. Videosurgery
Miniinv 2009; 4: 102-9. 
12. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastro-
esophageal reflux as a risk factor for esophageal adenocarcino-
ma. N Engl J Med 1999; 340: 825-31.
13. DeMeester SR. Adenocarcinoma of the esophagus and cardia:
a review of the disease and its treatment. Ann Surg Oncol 2006;
13: 12-30.
14. Milkes D, Gerson LB, Triadafilopoulos G. Complete elimination of
reflux symptoms does not guarantee normalization of intrae-
sophageal and intragastric pH in patients with gastroesophageal
reflux disease (GERD). Am J Gastroenterol 2004; 99: 991-6.
15. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of
Barrett's oesophagus during omeprazole treatment: a ran-
domised double blind study. Gut 1999; 45: 489-94. 
16. Chaves P, Pereira AD, Cruz C, et al. Recurrent columnar-lined
esophageal segments: study of the phenotypic characteristics
using intestinal markers. Dis Esophagus 2002; 15: 282-6.
17. Ertan A, Younes M. Barrett's esophagus. Dig Dis Sci 2000; 45:
1670-3.
18. Kahaleh M, Van Laethem JL, Nagy N, et al. Long-term follow-up
and factors predictive of recurrence in Barrett's esophagus 
treated by argon plasma coagulation and acid suppression.
Endoscopy 2002; 34: 950-5.
19. Wang KK, Sampliner RE. Practice Parameters Committee of the
American College of Gastroenterology, Updated guidelines 2008
for the diagnosis, surveillance and therapy of Barrett's esopha-
gus. Am J Gastroenterol 2008; 103: 788-97.
20. Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett's epi -
the lium by endoscopic argon plasma coagulation in combina -
tion with high-dose omeprazole. Gastrointest Endosc 2000; 51: 
659-63.
21. Sharma P, Sampliner R. Barrett’s esophagus, and esophageal
adenocarcinoma. Blackwell Publishing 2006.
22. Parrilla P, Martínez de Haro LF, Ortiz A, et al. Long-term results of
a randomized prospective study comparing medical and surgical
treatment of Barrett's esophagus. Ann Surg 2003; 237: 291-8.
23. Eubanks TR, Omelanczuk P, Richards C, et al. Outcomes of
laparoscopic antireflux procedures. Am J Surg 2000; 179: 391-5.
24. Stein HJ, Kauer WK, Feussner H, Siewert JR. Bile reflux in benign
and malignant Barrett's esophagus: effect of medical acid sup-
pression and Nissen fundoplication. J Gastrointest Surg 1998; 2:
333-41.
Marcin Migaczewski, Michał Pędziwiatr, Maciej Matłok, Andrzej Budzyński
Videosurgery and Other Miniinvasive Techniques 2, June/2013 145
25. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroe-
sophageal reflux: relationship to pH and importance in Barrett's
esophagus. Gastroenterology 1994; 107: 747-54.
26. Brand DL, Ylvisaker JT, Gelfand M, Pope CE 2nd. Regression of
columnar esophageal (Barrett's) epithelium after anti-reflux sur-
gery. N Engl J Med 1980; 302: 844-8.
27. Farrell TM, Smith CD, Metreveli RE, et al. Fundoplication provides
effective and durable symptom relief in patients with Barrett’s
esophagus. Am J Surg 1999; 178: 18-21.
28. Low DE, Levine DS, Dail DH, Kozarek RA. Histological and
anatomic changes in Barrett's esophagus after antireflux sur-
gery. Am J Gastroenterol 1999; 94: 80-5.
29. DeMeester SR, Campos GM, DeMeester TR, et al. The impact of
an antireflux procedure on intestinal metaplasia of the cardia.
Ann Surg 1998; 228: 547-56.
30. Dallemagne B, Weerts J, Markiewicz S, et al. Clinical results of
laparoscopic fundoplication at ten years after surgery. Surg
Endosc 2006; 20: 159-65.
31. Swanstrom LL. Management of patients with gastroesophageal
reflux disease and esophageal or gastric dysmotility. J Gastroin-
test Surg 2001; 5: 448-50.
32. Hunter JG, Smith CD, Branum GD, et al. Laparoscopic fundopli-
cation failures: patterns of failure and response to fundoplica-
tion revision. Ann Surg 1999; 230: 595-604.
Received: 14.10.2012, revised: 15.11.2012, accepted: 29.11.2012.
Laparoscopic Nissen fundoplication in the treatment of Barrett’s esophagus – 10 years of experience
